![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with BCR-ABL1 transcript level ≤10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
Acknowledgements
In particular, we thank data-managers Radek Minarik, Jana Rysava, Katerina Khaddourova, Jana Kralova, Eva Valouskova, and Martina Januskova for data collection. We also thank Rich Zimmerman for his English text review and corrections.
Disclosure statement
D.Z. served on a speakers bureau for Bristol Myers Squibb and Angelini, as a member of Advisory board for Novartis and Incyte, and as a consultant for Angelini. J.M. received research funding from Novartis, Bristol Myers Squibb and Angelini, and serves on a speakers bureau for Novartis and Bristol Myers Squibb. Other authors declare no potential conflict of interest.